nodes	percent_of_prediction	percent_of_DWPC	metapath
Dantrolene—RYR3—smooth muscle tissue—colon cancer	0.0379	0.192	CbGeAlD
Dantrolene—RYR3—lymphoid tissue—colon cancer	0.0303	0.153	CbGeAlD
Dantrolene—RYR3—digestive system—colon cancer	0.0299	0.151	CbGeAlD
Dantrolene—RYR1—smooth muscle tissue—colon cancer	0.0272	0.137	CbGeAlD
Dantrolene—RYR3—vagina—colon cancer	0.0264	0.134	CbGeAlD
Dantrolene—RYR1—vagina—colon cancer	0.0189	0.0959	CbGeAlD
Dantrolene—RYR1—liver—colon cancer	0.016	0.0809	CbGeAlD
Dantrolene—Extravasation—Irinotecan—colon cancer	0.0079	0.00985	CcSEcCtD
Dantrolene—Speech disorder—Fluorouracil—colon cancer	0.00768	0.00957	CcSEcCtD
Dantrolene—Extravasation—Fluorouracil—colon cancer	0.00757	0.00943	CcSEcCtD
Dantrolene—Lacrimation increased—Irinotecan—colon cancer	0.00748	0.00933	CcSEcCtD
Dantrolene—Respiratory failure—Vincristine—colon cancer	0.00721	0.00899	CcSEcCtD
Dantrolene—Lacrimation increased—Fluorouracil—colon cancer	0.00717	0.00893	CcSEcCtD
Dantrolene—Intestinal obstruction—Capecitabine—colon cancer	0.00677	0.00844	CcSEcCtD
Dantrolene—Pleural effusion—Capecitabine—colon cancer	0.00603	0.00751	CcSEcCtD
Dantrolene—Hepatotoxicity—Capecitabine—colon cancer	0.00598	0.00745	CcSEcCtD
Dantrolene—Coagulopathy—Capecitabine—colon cancer	0.00593	0.00739	CcSEcCtD
Dantrolene—Thrombophlebitis—Irinotecan—colon cancer	0.00578	0.00721	CcSEcCtD
Dantrolene—Hepatic failure—Vincristine—colon cancer	0.00572	0.00713	CcSEcCtD
Dantrolene—Dysphonia—Capecitabine—colon cancer	0.00561	0.00699	CcSEcCtD
Dantrolene—Eruption—Methotrexate—colon cancer	0.00559	0.00696	CcSEcCtD
Dantrolene—Thrombophlebitis—Fluorouracil—colon cancer	0.00554	0.0069	CcSEcCtD
Dantrolene—Swelling—Fluorouracil—colon cancer	0.00543	0.00677	CcSEcCtD
Dantrolene—Visual disturbance—Irinotecan—colon cancer	0.00528	0.00658	CcSEcCtD
Dantrolene—Pain in extremity—Vincristine—colon cancer	0.00514	0.00641	CcSEcCtD
Dantrolene—Lacrimation increased—Capecitabine—colon cancer	0.00501	0.00624	CcSEcCtD
Dantrolene—Gastrointestinal haemorrhage—Irinotecan—colon cancer	0.00501	0.00624	CcSEcCtD
Dantrolene—Nocturia—Capecitabine—colon cancer	0.00498	0.0062	CcSEcCtD
Dantrolene—Cardiac failure—Fluorouracil—colon cancer	0.00491	0.00612	CcSEcCtD
Dantrolene—Urinary retention—Vincristine—colon cancer	0.00489	0.00609	CcSEcCtD
Dantrolene—Gastrointestinal haemorrhage—Fluorouracil—colon cancer	0.00479	0.00597	CcSEcCtD
Dantrolene—Injection site reaction—Capecitabine—colon cancer	0.00459	0.00572	CcSEcCtD
Dantrolene—CYP3A4—renal system—colon cancer	0.00454	0.023	CbGeAlD
Dantrolene—Muscular weakness—Vincristine—colon cancer	0.00453	0.00565	CcSEcCtD
Dantrolene—Pleural effusion—Methotrexate—colon cancer	0.00449	0.00559	CcSEcCtD
Dantrolene—Urinary incontinence—Capecitabine—colon cancer	0.00446	0.00555	CcSEcCtD
Dantrolene—Hepatotoxicity—Methotrexate—colon cancer	0.00445	0.00555	CcSEcCtD
Dantrolene—Necrosis—Methotrexate—colon cancer	0.00438	0.00546	CcSEcCtD
Dantrolene—Muscular weakness—Fluorouracil—colon cancer	0.00423	0.00527	CcSEcCtD
Dantrolene—Dysphagia—Fluorouracil—colon cancer	0.00414	0.00516	CcSEcCtD
Dantrolene—Eosinophilia—Fluorouracil—colon cancer	0.0041	0.00511	CcSEcCtD
Dantrolene—Speech disorder—Methotrexate—colon cancer	0.00399	0.00498	CcSEcCtD
Dantrolene—Depression—Vincristine—colon cancer	0.00395	0.00492	CcSEcCtD
Dantrolene—Extravasation—Methotrexate—colon cancer	0.00394	0.00491	CcSEcCtD
Dantrolene—Phlebitis—Capecitabine—colon cancer	0.00389	0.00485	CcSEcCtD
Dantrolene—Thrombophlebitis—Capecitabine—colon cancer	0.00387	0.00482	CcSEcCtD
Dantrolene—Swelling—Capecitabine—colon cancer	0.0038	0.00473	CcSEcCtD
Dantrolene—Sweating—Vincristine—colon cancer	0.0038	0.00473	CcSEcCtD
Dantrolene—Renal failure—Irinotecan—colon cancer	0.00379	0.00473	CcSEcCtD
Dantrolene—Hepatic failure—Capecitabine—colon cancer	0.00373	0.00465	CcSEcCtD
Dantrolene—CYP3A4—digestive system—colon cancer	0.00373	0.0189	CbGeAlD
Dantrolene—Sweating—Irinotecan—colon cancer	0.0037	0.00461	CcSEcCtD
Dantrolene—Respiratory failure—Methotrexate—colon cancer	0.0035	0.00436	CcSEcCtD
Dantrolene—Haemoglobin—Irinotecan—colon cancer	0.00348	0.00434	CcSEcCtD
Dantrolene—Haemorrhage—Irinotecan—colon cancer	0.00346	0.00432	CcSEcCtD
Dantrolene—Cardiac failure—Capecitabine—colon cancer	0.00343	0.00428	CcSEcCtD
Dantrolene—Diplopia—Capecitabine—colon cancer	0.00335	0.00418	CcSEcCtD
Dantrolene—Pain in extremity—Capecitabine—colon cancer	0.00335	0.00418	CcSEcCtD
Dantrolene—Gastrointestinal haemorrhage—Capecitabine—colon cancer	0.00335	0.00418	CcSEcCtD
Dantrolene—Visual impairment—Irinotecan—colon cancer	0.00334	0.00416	CcSEcCtD
Dantrolene—Haemoglobin—Fluorouracil—colon cancer	0.00333	0.00415	CcSEcCtD
Dantrolene—Haemorrhage—Fluorouracil—colon cancer	0.00332	0.00413	CcSEcCtD
Dantrolene—Aplastic anaemia—Methotrexate—colon cancer	0.00323	0.00402	CcSEcCtD
Dantrolene—Flushing—Irinotecan—colon cancer	0.00321	0.00401	CcSEcCtD
Dantrolene—Urinary retention—Capecitabine—colon cancer	0.00319	0.00397	CcSEcCtD
Dantrolene—Chills—Irinotecan—colon cancer	0.00311	0.00387	CcSEcCtD
Dantrolene—Pulmonary oedema—Methotrexate—colon cancer	0.00306	0.00381	CcSEcCtD
Dantrolene—Back pain—Vincristine—colon cancer	0.00299	0.00373	CcSEcCtD
Dantrolene—Muscular weakness—Capecitabine—colon cancer	0.00296	0.00368	CcSEcCtD
Dantrolene—Back pain—Irinotecan—colon cancer	0.00292	0.00363	CcSEcCtD
Dantrolene—Dysphagia—Capecitabine—colon cancer	0.0029	0.00361	CcSEcCtD
Dantrolene—Erythema—Fluorouracil—colon cancer	0.00289	0.0036	CcSEcCtD
Dantrolene—Thrombophlebitis—Methotrexate—colon cancer	0.00288	0.00359	CcSEcCtD
Dantrolene—Anaemia—Vincristine—colon cancer	0.00286	0.00357	CcSEcCtD
Dantrolene—Ill-defined disorder—Irinotecan—colon cancer	0.0028	0.00349	CcSEcCtD
Dantrolene—Anaemia—Irinotecan—colon cancer	0.00279	0.00347	CcSEcCtD
Dantrolene—CYP3A4—liver—colon cancer	0.00278	0.0141	CbGeAlD
Dantrolene—Hepatic failure—Methotrexate—colon cancer	0.00278	0.00346	CcSEcCtD
Dantrolene—Leukopenia—Vincristine—colon cancer	0.00277	0.00345	CcSEcCtD
Dantrolene—Vision blurred—Fluorouracil—colon cancer	0.00272	0.00339	CcSEcCtD
Dantrolene—Malaise—Irinotecan—colon cancer	0.00272	0.00339	CcSEcCtD
Dantrolene—Leukopenia—Irinotecan—colon cancer	0.0027	0.00336	CcSEcCtD
Dantrolene—Convulsion—Vincristine—colon cancer	0.00268	0.00334	CcSEcCtD
Dantrolene—Hypertension—Vincristine—colon cancer	0.00267	0.00333	CcSEcCtD
Dantrolene—Anaemia—Fluorouracil—colon cancer	0.00267	0.00333	CcSEcCtD
Dantrolene—Myalgia—Vincristine—colon cancer	0.00264	0.00328	CcSEcCtD
Dantrolene—Visual disturbance—Methotrexate—colon cancer	0.00263	0.00328	CcSEcCtD
Dantrolene—Hypertension—Irinotecan—colon cancer	0.0026	0.00324	CcSEcCtD
Dantrolene—Leukopenia—Fluorouracil—colon cancer	0.00258	0.00322	CcSEcCtD
Dantrolene—Depression—Capecitabine—colon cancer	0.00257	0.00321	CcSEcCtD
Dantrolene—Renal failure—Capecitabine—colon cancer	0.00254	0.00316	CcSEcCtD
Dantrolene—Discomfort—Irinotecan—colon cancer	0.00254	0.00316	CcSEcCtD
Dantrolene—Anaphylactic shock—Vincristine—colon cancer	0.00253	0.00315	CcSEcCtD
Dantrolene—Convulsion—Fluorouracil—colon cancer	0.0025	0.00312	CcSEcCtD
Dantrolene—Confusional state—Irinotecan—colon cancer	0.00248	0.00309	CcSEcCtD
Dantrolene—Thrombocytopenia—Vincristine—colon cancer	0.00247	0.00308	CcSEcCtD
Dantrolene—Haematuria—Capecitabine—colon cancer	0.00246	0.00307	CcSEcCtD
Dantrolene—Anaphylactic shock—Irinotecan—colon cancer	0.00246	0.00307	CcSEcCtD
Dantrolene—Myalgia—Fluorouracil—colon cancer	0.00246	0.00306	CcSEcCtD
Dantrolene—Hyperhidrosis—Vincristine—colon cancer	0.00244	0.00304	CcSEcCtD
Dantrolene—Discomfort—Fluorouracil—colon cancer	0.00243	0.00303	CcSEcCtD
Dantrolene—Thrombocytopenia—Irinotecan—colon cancer	0.00241	0.003	CcSEcCtD
Dantrolene—Anorexia—Vincristine—colon cancer	0.00241	0.003	CcSEcCtD
Dantrolene—Hyperhidrosis—Irinotecan—colon cancer	0.00238	0.00296	CcSEcCtD
Dantrolene—Confusional state—Fluorouracil—colon cancer	0.00238	0.00296	CcSEcCtD
Dantrolene—Anaphylactic shock—Fluorouracil—colon cancer	0.00236	0.00294	CcSEcCtD
Dantrolene—Anorexia—Irinotecan—colon cancer	0.00235	0.00292	CcSEcCtD
Dantrolene—Haemoglobin—Capecitabine—colon cancer	0.00233	0.0029	CcSEcCtD
Dantrolene—Hepatitis—Capecitabine—colon cancer	0.00232	0.00289	CcSEcCtD
Dantrolene—Haemorrhage—Capecitabine—colon cancer	0.00232	0.00289	CcSEcCtD
Dantrolene—Thrombocytopenia—Fluorouracil—colon cancer	0.00231	0.00288	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Vincristine—colon cancer	0.0023	0.00287	CcSEcCtD
Dantrolene—Tachycardia—Fluorouracil—colon cancer	0.0023	0.00287	CcSEcCtD
Dantrolene—Insomnia—Vincristine—colon cancer	0.00229	0.00285	CcSEcCtD
Dantrolene—Anorexia—Fluorouracil—colon cancer	0.00225	0.0028	CcSEcCtD
Dantrolene—Visual impairment—Capecitabine—colon cancer	0.00223	0.00278	CcSEcCtD
Dantrolene—Insomnia—Irinotecan—colon cancer	0.00223	0.00277	CcSEcCtD
Dantrolene—Decreased appetite—Vincristine—colon cancer	0.0022	0.00274	CcSEcCtD
Dantrolene—Somnolence—Irinotecan—colon cancer	0.00219	0.00273	CcSEcCtD
Dantrolene—Fatigue—Vincristine—colon cancer	0.00218	0.00271	CcSEcCtD
Dantrolene—Dyspepsia—Irinotecan—colon cancer	0.00217	0.0027	CcSEcCtD
Dantrolene—Pain—Vincristine—colon cancer	0.00216	0.00269	CcSEcCtD
Dantrolene—Constipation—Vincristine—colon cancer	0.00216	0.00269	CcSEcCtD
Dantrolene—Flushing—Capecitabine—colon cancer	0.00215	0.00268	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00215	0.00268	CcSEcCtD
Dantrolene—Decreased appetite—Irinotecan—colon cancer	0.00214	0.00267	CcSEcCtD
Dantrolene—Eosinophilia—Methotrexate—colon cancer	0.00213	0.00266	CcSEcCtD
Dantrolene—Insomnia—Fluorouracil—colon cancer	0.00213	0.00266	CcSEcCtD
Dantrolene—Fatigue—Irinotecan—colon cancer	0.00212	0.00264	CcSEcCtD
Dantrolene—Pain—Irinotecan—colon cancer	0.0021	0.00262	CcSEcCtD
Dantrolene—Constipation—Irinotecan—colon cancer	0.0021	0.00262	CcSEcCtD
Dantrolene—Somnolence—Fluorouracil—colon cancer	0.00209	0.00261	CcSEcCtD
Dantrolene—Chills—Capecitabine—colon cancer	0.00208	0.00259	CcSEcCtD
Dantrolene—Dyspepsia—Fluorouracil—colon cancer	0.00207	0.00258	CcSEcCtD
Dantrolene—Gastrointestinal pain—Vincristine—colon cancer	0.00207	0.00257	CcSEcCtD
Dantrolene—Decreased appetite—Fluorouracil—colon cancer	0.00205	0.00255	CcSEcCtD
Dantrolene—Feeling abnormal—Irinotecan—colon cancer	0.00203	0.00253	CcSEcCtD
Dantrolene—Erythema—Capecitabine—colon cancer	0.00202	0.00251	CcSEcCtD
Dantrolene—Pain—Fluorouracil—colon cancer	0.00202	0.00251	CcSEcCtD
Dantrolene—Gastrointestinal pain—Irinotecan—colon cancer	0.00201	0.00251	CcSEcCtD
Dantrolene—Body temperature increased—Vincristine—colon cancer	0.002	0.00249	CcSEcCtD
Dantrolene—Abdominal pain—Vincristine—colon cancer	0.002	0.00249	CcSEcCtD
Dantrolene—Dysgeusia—Capecitabine—colon cancer	0.00198	0.00246	CcSEcCtD
Dantrolene—Back pain—Capecitabine—colon cancer	0.00195	0.00243	CcSEcCtD
Dantrolene—Abdominal pain—Irinotecan—colon cancer	0.00195	0.00242	CcSEcCtD
Dantrolene—Body temperature increased—Irinotecan—colon cancer	0.00195	0.00242	CcSEcCtD
Dantrolene—Feeling abnormal—Fluorouracil—colon cancer	0.00194	0.00242	CcSEcCtD
Dantrolene—Drowsiness—Methotrexate—colon cancer	0.00192	0.0024	CcSEcCtD
Dantrolene—Depression—Methotrexate—colon cancer	0.00192	0.00239	CcSEcCtD
Dantrolene—Vision blurred—Capecitabine—colon cancer	0.0019	0.00237	CcSEcCtD
Dantrolene—Renal failure—Methotrexate—colon cancer	0.00189	0.00235	CcSEcCtD
Dantrolene—Ill-defined disorder—Capecitabine—colon cancer	0.00187	0.00233	CcSEcCtD
Dantrolene—Urticaria—Fluorouracil—colon cancer	0.00187	0.00233	CcSEcCtD
Dantrolene—Anaemia—Capecitabine—colon cancer	0.00186	0.00232	CcSEcCtD
Dantrolene—Body temperature increased—Fluorouracil—colon cancer	0.00186	0.00232	CcSEcCtD
Dantrolene—Hypersensitivity—Vincristine—colon cancer	0.00186	0.00232	CcSEcCtD
Dantrolene—Sweating—Methotrexate—colon cancer	0.00184	0.0023	CcSEcCtD
Dantrolene—Haematuria—Methotrexate—colon cancer	0.00183	0.00228	CcSEcCtD
Dantrolene—Malaise—Capecitabine—colon cancer	0.00182	0.00227	CcSEcCtD
Dantrolene—Hypersensitivity—Irinotecan—colon cancer	0.00181	0.00226	CcSEcCtD
Dantrolene—Asthenia—Vincristine—colon cancer	0.00181	0.00226	CcSEcCtD
Dantrolene—Leukopenia—Capecitabine—colon cancer	0.00181	0.00225	CcSEcCtD
Dantrolene—Asthenia—Irinotecan—colon cancer	0.00177	0.0022	CcSEcCtD
Dantrolene—Hypertension—Capecitabine—colon cancer	0.00174	0.00217	CcSEcCtD
Dantrolene—Hypersensitivity—Fluorouracil—colon cancer	0.00174	0.00216	CcSEcCtD
Dantrolene—Haemoglobin—Methotrexate—colon cancer	0.00173	0.00216	CcSEcCtD
Dantrolene—Diarrhoea—Vincristine—colon cancer	0.00173	0.00215	CcSEcCtD
Dantrolene—Haemorrhage—Methotrexate—colon cancer	0.00173	0.00215	CcSEcCtD
Dantrolene—Hepatitis—Methotrexate—colon cancer	0.00173	0.00215	CcSEcCtD
Dantrolene—Myalgia—Capecitabine—colon cancer	0.00172	0.00214	CcSEcCtD
Dantrolene—Discomfort—Capecitabine—colon cancer	0.0017	0.00212	CcSEcCtD
Dantrolene—Diarrhoea—Irinotecan—colon cancer	0.00168	0.0021	CcSEcCtD
Dantrolene—Dry mouth—Capecitabine—colon cancer	0.00168	0.00209	CcSEcCtD
Dantrolene—Dizziness—Vincristine—colon cancer	0.00167	0.00208	CcSEcCtD
Dantrolene—Pruritus—Fluorouracil—colon cancer	0.00167	0.00208	CcSEcCtD
Dantrolene—Visual impairment—Methotrexate—colon cancer	0.00166	0.00207	CcSEcCtD
Dantrolene—Confusional state—Capecitabine—colon cancer	0.00166	0.00207	CcSEcCtD
Dantrolene—Dizziness—Irinotecan—colon cancer	0.00163	0.00203	CcSEcCtD
Dantrolene—Diarrhoea—Fluorouracil—colon cancer	0.00161	0.00201	CcSEcCtD
Dantrolene—Thrombocytopenia—Capecitabine—colon cancer	0.00161	0.00201	CcSEcCtD
Dantrolene—Tachycardia—Capecitabine—colon cancer	0.00161	0.002	CcSEcCtD
Dantrolene—Vomiting—Vincristine—colon cancer	0.00161	0.002	CcSEcCtD
Dantrolene—Rash—Vincristine—colon cancer	0.00159	0.00199	CcSEcCtD
Dantrolene—Hyperhidrosis—Capecitabine—colon cancer	0.00159	0.00198	CcSEcCtD
Dantrolene—Dermatitis—Vincristine—colon cancer	0.00159	0.00198	CcSEcCtD
Dantrolene—Headache—Vincristine—colon cancer	0.00158	0.00197	CcSEcCtD
Dantrolene—Anorexia—Capecitabine—colon cancer	0.00157	0.00196	CcSEcCtD
Dantrolene—Vomiting—Irinotecan—colon cancer	0.00156	0.00195	CcSEcCtD
Dantrolene—Dizziness—Fluorouracil—colon cancer	0.00156	0.00194	CcSEcCtD
Dantrolene—Rash—Irinotecan—colon cancer	0.00155	0.00193	CcSEcCtD
Dantrolene—Dermatitis—Irinotecan—colon cancer	0.00155	0.00193	CcSEcCtD
Dantrolene—Chills—Methotrexate—colon cancer	0.00155	0.00193	CcSEcCtD
Dantrolene—Headache—Irinotecan—colon cancer	0.00154	0.00192	CcSEcCtD
Dantrolene—Erythema—Methotrexate—colon cancer	0.0015	0.00187	CcSEcCtD
Dantrolene—Nausea—Vincristine—colon cancer	0.0015	0.00187	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Capecitabine—colon cancer	0.0015	0.00187	CcSEcCtD
Dantrolene—Vomiting—Fluorouracil—colon cancer	0.0015	0.00187	CcSEcCtD
Dantrolene—Insomnia—Capecitabine—colon cancer	0.00149	0.00186	CcSEcCtD
Dantrolene—Rash—Fluorouracil—colon cancer	0.00149	0.00185	CcSEcCtD
Dantrolene—Dermatitis—Fluorouracil—colon cancer	0.00148	0.00185	CcSEcCtD
Dantrolene—Headache—Fluorouracil—colon cancer	0.00148	0.00184	CcSEcCtD
Dantrolene—Dysgeusia—Methotrexate—colon cancer	0.00147	0.00183	CcSEcCtD
Dantrolene—Nausea—Irinotecan—colon cancer	0.00146	0.00182	CcSEcCtD
Dantrolene—Back pain—Methotrexate—colon cancer	0.00145	0.00181	CcSEcCtD
Dantrolene—Dyspepsia—Capecitabine—colon cancer	0.00145	0.00181	CcSEcCtD
Dantrolene—Decreased appetite—Capecitabine—colon cancer	0.00143	0.00178	CcSEcCtD
Dantrolene—Fatigue—Capecitabine—colon cancer	0.00142	0.00177	CcSEcCtD
Dantrolene—Vision blurred—Methotrexate—colon cancer	0.00142	0.00176	CcSEcCtD
Dantrolene—Pain—Capecitabine—colon cancer	0.00141	0.00175	CcSEcCtD
Dantrolene—Constipation—Capecitabine—colon cancer	0.00141	0.00175	CcSEcCtD
Dantrolene—Nausea—Fluorouracil—colon cancer	0.0014	0.00174	CcSEcCtD
Dantrolene—Ill-defined disorder—Methotrexate—colon cancer	0.00139	0.00174	CcSEcCtD
Dantrolene—Anaemia—Methotrexate—colon cancer	0.00139	0.00173	CcSEcCtD
Dantrolene—Feeling abnormal—Capecitabine—colon cancer	0.00136	0.00169	CcSEcCtD
Dantrolene—Malaise—Methotrexate—colon cancer	0.00135	0.00169	CcSEcCtD
Dantrolene—Gastrointestinal pain—Capecitabine—colon cancer	0.00135	0.00168	CcSEcCtD
Dantrolene—Leukopenia—Methotrexate—colon cancer	0.00134	0.00168	CcSEcCtD
Dantrolene—Urticaria—Capecitabine—colon cancer	0.00131	0.00163	CcSEcCtD
Dantrolene—Abdominal pain—Capecitabine—colon cancer	0.0013	0.00162	CcSEcCtD
Dantrolene—Body temperature increased—Capecitabine—colon cancer	0.0013	0.00162	CcSEcCtD
Dantrolene—Convulsion—Methotrexate—colon cancer	0.0013	0.00162	CcSEcCtD
Dantrolene—Myalgia—Methotrexate—colon cancer	0.00128	0.00159	CcSEcCtD
Dantrolene—Discomfort—Methotrexate—colon cancer	0.00126	0.00157	CcSEcCtD
Dantrolene—Confusional state—Methotrexate—colon cancer	0.00124	0.00154	CcSEcCtD
Dantrolene—Anaphylactic shock—Methotrexate—colon cancer	0.00123	0.00153	CcSEcCtD
Dantrolene—Hypersensitivity—Capecitabine—colon cancer	0.00121	0.00151	CcSEcCtD
Dantrolene—Thrombocytopenia—Methotrexate—colon cancer	0.0012	0.0015	CcSEcCtD
Dantrolene—Hyperhidrosis—Methotrexate—colon cancer	0.00119	0.00148	CcSEcCtD
Dantrolene—Asthenia—Capecitabine—colon cancer	0.00118	0.00147	CcSEcCtD
Dantrolene—Anorexia—Methotrexate—colon cancer	0.00117	0.00146	CcSEcCtD
Dantrolene—Pruritus—Capecitabine—colon cancer	0.00117	0.00145	CcSEcCtD
Dantrolene—Diarrhoea—Capecitabine—colon cancer	0.00113	0.0014	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Methotrexate—colon cancer	0.00112	0.00139	CcSEcCtD
Dantrolene—Insomnia—Methotrexate—colon cancer	0.00111	0.00138	CcSEcCtD
Dantrolene—Somnolence—Methotrexate—colon cancer	0.00109	0.00136	CcSEcCtD
Dantrolene—Dizziness—Capecitabine—colon cancer	0.00109	0.00136	CcSEcCtD
Dantrolene—Dyspepsia—Methotrexate—colon cancer	0.00108	0.00134	CcSEcCtD
Dantrolene—Decreased appetite—Methotrexate—colon cancer	0.00107	0.00133	CcSEcCtD
Dantrolene—Fatigue—Methotrexate—colon cancer	0.00106	0.00132	CcSEcCtD
Dantrolene—Pain—Methotrexate—colon cancer	0.00105	0.00131	CcSEcCtD
Dantrolene—Vomiting—Capecitabine—colon cancer	0.00105	0.0013	CcSEcCtD
Dantrolene—Rash—Capecitabine—colon cancer	0.00104	0.00129	CcSEcCtD
Dantrolene—Dermatitis—Capecitabine—colon cancer	0.00104	0.00129	CcSEcCtD
Dantrolene—Headache—Capecitabine—colon cancer	0.00103	0.00129	CcSEcCtD
Dantrolene—Feeling abnormal—Methotrexate—colon cancer	0.00101	0.00126	CcSEcCtD
Dantrolene—Gastrointestinal pain—Methotrexate—colon cancer	0.001	0.00125	CcSEcCtD
Dantrolene—Nausea—Capecitabine—colon cancer	0.000978	0.00122	CcSEcCtD
Dantrolene—Urticaria—Methotrexate—colon cancer	0.000974	0.00121	CcSEcCtD
Dantrolene—Abdominal pain—Methotrexate—colon cancer	0.000969	0.00121	CcSEcCtD
Dantrolene—Body temperature increased—Methotrexate—colon cancer	0.000969	0.00121	CcSEcCtD
Dantrolene—Hypersensitivity—Methotrexate—colon cancer	0.000903	0.00113	CcSEcCtD
Dantrolene—Asthenia—Methotrexate—colon cancer	0.00088	0.0011	CcSEcCtD
Dantrolene—Pruritus—Methotrexate—colon cancer	0.000867	0.00108	CcSEcCtD
Dantrolene—Diarrhoea—Methotrexate—colon cancer	0.000839	0.00105	CcSEcCtD
Dantrolene—Dizziness—Methotrexate—colon cancer	0.000811	0.00101	CcSEcCtD
Dantrolene—Vomiting—Methotrexate—colon cancer	0.000779	0.000971	CcSEcCtD
Dantrolene—Rash—Methotrexate—colon cancer	0.000773	0.000963	CcSEcCtD
Dantrolene—Dermatitis—Methotrexate—colon cancer	0.000772	0.000962	CcSEcCtD
Dantrolene—Headache—Methotrexate—colon cancer	0.000768	0.000957	CcSEcCtD
Dantrolene—Nausea—Methotrexate—colon cancer	0.000728	0.000907	CcSEcCtD
